What is eTheRNA?
Headquartered in Flanders, Belgium, and founded in 2013, eTheRNA is at the forefront of applying messenger RNA (mRNA) technology to create innovative immunotherapies. The company's focus on both oncology and infectious diseases positions it within a critical and rapidly evolving sector of biotechnology. Its strategic approach leverages the potential of mRNA to stimulate potent immune responses, offering a promising avenue for therapeutic development.
How much funding has eTheRNA raised?
eTheRNA has raised a total of $103.7M across 2 funding rounds:
Series A
$26.7M
Series B
$77M
Series A (2016): $26.7M with participation from Omega Funds, Boehringer Ingelheim, Life Sciences Partners, Fund+ NV/SA, and PMV
Series B (2022): $77M led by Fund+ NV/SA, Professor Kenneth Chien, Omega Fund Management, PMV, Novalis LifeSciences, Life Sciences Partners, and Boehringer Ingelheim
Key Investors in eTheRNA
Omega Funds
Omega Funds is a venture capital firm with a primary investment focus on drug discovery and development companies, specializing in life science and healthcare.
Boehringer Ingelheim
Boehringer Ingelheim is a global pharmaceutical company dedicated to the research, development, manufacturing, and marketing of new medicines.
Life Sciences Partners
Life Sciences Partners (LSP) is a European investment firm focused on the life sciences sector, backing innovative companies from early stage to growth.
What's next for eTheRNA?
The recent major strategic investment in eTheRNA signals a strong validation of its technological platform and therapeutic pipeline. This capital infusion is expected to accelerate the company's clinical development programs, potentially enabling further research, expansion of its therapeutic targets, and progression towards commercialization. The backing from prominent life science investors suggests a clear path forward for advancing its mRNA-based treatments.
See full eTheRNA company page
